Lipid Emulsion
ApprovedSmall molecule
Lipid Emulsion is one of 92 small molecule programs targeting Abscess. It is currently in Approved.
3
Indications
7
Total Trials
2
Active Trials
91
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
223 competitors in Toxicity
#DrugCompanyPhaseTrials
1Mucosta
OtsukaPhase 3
Paracetamol
GSKPhase 3
Lipid Emulsion
UUniversity of Rochester
Approved
Sodium-Selenite
SStanford University
Phase 3
Gnrha
SSecond Affiliated Hospital of Wenzhou Medical University
Phase 3
Trizivir
GSKPhase 3
Cysteine Hydrochloride
NovartisPreclinical
Imfinzi
AstraZenecaPreclinical
Cellcept
NovartisPreclinical
Afinitor
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lipid Emulsion3 trials
Abscess2 trials
Toxicity1 trial
Poisoning1 trial
Role of Intravenous Lipid Emulsion in Improving Coma of Acute Antipsychotics Poisoning
Unknown status·—·N/A·NCT04807634·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lipid Emulsion. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Rochester